Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 4/20 | 0.39 |
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | HTR2C | P28335 | 3/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1580100 | 0.86 | POLB (0.54) | DPP4DPP7POLB | |
| SCHEMBL14833502 | 0.84 | MMP1 (0.44) | MAOAMAOB | |
| SCHEMBL31542128 | 0.84 | DPP4 (0.42) | LMNADPP4DPP7HTR2AHTR2C | |
| SCHEMBL7230204 | 0.82 | ADRB1 (0.44) | — | |
| SCHEMBL6984335 | 0.81 | DPP4 (0.47) | DPP4DPP7HTR2AHTR2CHTR2B | |
| SCHEMBL7400548 | 0.78 | MAOB (0.39) | MAOAMAOBHTR2AHTR2CHTR2B | |
| SCHEMBL7590748 | 0.77 | POLB (0.42) | DPP4DPP7MAOBPOLB | |
| SCHEMBL14833618 | 0.76 | CHRNA7 (0.45) | LMNA | |
| SCHEMBL16261916 | 0.76 | DPP4 (0.41) | DPP4DPP7MAOAMAOBHTR2A | |
| Tert-Butyl Formate SCHEMBL28018953 | 0.75 | POLB (0.43) | DPP4DPP7HTR2AHTR2CPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1278755-A2 | AZOLE COMPOUNDS AS THERAPEUTIC AGENTS FOR FUNGAL INFECTIONS | Ranbaxy Laboratories, Limited (IN) | 2003-01-29 | — | — | EP | claimed |
| WO-2001066551-A2 | AZOLE COMPOUNDS AS THERAPEUTIC AGENTS FOR FUNGAL INFECTIONS | RANBAXY LABORATORIES LIMITED (IN) | 2001-09-13 | — | — | WO | claimed |
| US-20100143455-A1 | Triazole antifungal agents | WU NIAN | 2010-06-10 | — | — | US | disclosed |
| US-6670363-B1 | 2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol -1-yl) propyl)-4-(4-(4-(4-chlorophenyl)-1-piperazinyl)phenyl) -3-(2H,4H)-1,2,4-triazolone; opportunistic fungal infections | RANBAXY LABORATORIES LIMITED (IN) | 2003-12-30 | — | — | US | disclosed |
| EP-1278755-A2 | AZOLE COMPOUNDS AS THERAPEUTIC AGENTS FOR FUNGAL INFECTIONS | Ranbaxy Laboratories, Limited (IN) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001066551-A2 | AZOLE COMPOUNDS AS THERAPEUTIC AGENTS FOR FUNGAL INFECTIONS | RANBAXY LABORATORIES LIMITED (IN) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143455-A1 | Triazole antifungal agents | CYP3A7, ERG28, UGT1A7 | LMNA 4116/4885DPP4 2287/4885DPP7 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.